Skip to content

Recursion Pharmaceuticals

US · RXRX #2649 by market cap Listed 2021
2.45 -0.27 -9.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Price chart

Pre-market 2.67 -1.84%
After-hours 2.51 +2.39%
Overnight 2.70 -0.74%
4.782.452.452026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on RXRX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is -31.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 23.8% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Gross margin 4.4% Better than 3%
Operating margin -872.8% Better than 3%
Net margin -868.3% Better than 3%
Return on equity -59.5% Better than 8%
Return on invested capital -56.6% Better than 5%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -30.0% Better than 18%
6-month return -18.6% Better than 29%
12-month return (ex latest month) -11.3% Better than 22%
Distance below 52-week high 53.2% Better than 16%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.5x Better than 88%
Debt to assets 5.3% Better than 79%
Interest coverage -355.3x Better than 3%
Analyst View B

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 50.0% Better than 26%
Upside to average target 170.6% Better than 92%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -23.08%
1M -33.06%
3M -26.65%
6M -17.23%
YTD -40.10%
1Y -36.36%
3Y -64.29%
5Y -87.63%

Key statistics

Price & volume

Prev close
2.72
Open
2.63
Day range
2.44 - 2.76
Avg price
2.55
Volume
29.88M
Turnover
76.24M
Amplitude
11.77%
52-week range
2.44 - 5.24

Valuation

P/E
-1.70
P/E (TTM)
-2.85
P/B
1.68
EPS
-1.44
Net profit
-896.77M
Net assets
906.11M

Share structure

Market cap
1.53B
Float cap
1.42B
Shares out
622.76M
Float shares
580.95M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-04-16
52-week range 0% of range
2.44 5.24

53.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-13.25M net over the window

Short interest

Shares short
142.27M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Recursion Pharmaceuticals (RXRX)?

Recursion Pharmaceuticals last traded at 2.45. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Recursion Pharmaceuticals's market cap?

About 1.53B.

What is the P/E ratio of Recursion Pharmaceuticals?

The trailing twelve-month P/E is -2.85. The Valuation tab shows it against the stock's own five-year range.

Does Recursion Pharmaceuticals pay a dividend?

Recursion Pharmaceuticals does not currently pay a regular dividend.

Is Recursion Pharmaceuticals a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 6.63, which implies 170.6% upside from the current price. This is not investment advice.

What is Recursion Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Recursion Pharmaceuticals a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:59:48 · For reference only, not investment advice and not tailored to your situation.

Recursion Pharmaceuticals discussion 0 comments

Add a comment